An Aib-modified antimicrobial peptide killed multi-drug resistant Pseudomonas at 1.56 µM with zero toxicity to blood cells even at 64× the effective dose.
1.56 µMkills multi-drug resistant Pseudomonas with a 64-fold safety margin over blood cell toxicity
What the researchers found
The rationally designed peptide 'Stripe' was modified using two helix-stabilization strategies: Aib (2-aminoisobutyric acid) incorporation and side-chain stapling.
The Aib-containing variant was dramatically potent: MIC of 3.125 micromolar against gram-positive S. aureus and an astonishing 1.56 micromolar against a multi-drug resistant Pseudomonas aeruginosa (MDRP) strain. For context, many AMPs require 10-100 micromolar to achieve similar effects.
Safety margin was exceptional: no significant hemolytic activity up to 100+ micromolar, meaning the therapeutic window was at least 64-fold (1.56 vs 100 micromolar).
Electrophysiology experiments explained the selectivity: the peptide formed stable pores in DOPE/DOPG bilayers (mimicking bacterial membranes, which are negatively charged) but not in DOPC bilayers (mimicking mammalian membranes, which are neutral). This charge-based selectivity is why the peptide kills bacteria but not human cells.
Why it matters
Multi-drug resistant Pseudomonas aeruginosa is one of the WHO's critical priority pathogens. This peptide kills it at very low concentrations with a wide safety margin. The Aib modification strategy is simple and generalizable, potentially applicable to other antimicrobial peptides to improve their potency.
The numbers in context
MIC: 1.56µM (MDRP), 3.125µM (S. aureus); no hemolysis >100µM; pores in DOPE/DOPG but not DOPC
How the study worked
Peptide chemistry and microbiology study. Stripe-based foldamers were designed computationally, synthesized, and tested for MIC against S. aureus and MDRP. Hemolysis assays measured red blood cell damage. Electrophysiology on model membranes (planar lipid bilayers) characterized pore formation in bacterial-like vs mammalian-like membranes.
Who was studied
S. aureus and multi-drug resistant P. aeruginosa; model membranes
What this study cannot tell us
Tested only against two bacterial species (one gram-positive, one gram-negative). In vitro only; no animal infection models. Pore formation was tested in artificial membranes, not real bacterial cells. Pharmacokinetics (blood stability, distribution, clearance) were not assessed. Cost of Aib-containing peptide synthesis may be higher than standard peptides.
How to read the evidence
Preliminary evidence from in vitro testing against two bacterial species. Exceptional numbers but no animal model data yet.
When this study was published
Published in 2020. The Aib modification strategy continues to be explored for antimicrobial peptide development.
The bigger picture
Multi-drug resistant Pseudomonas is one of the WHO's critical priority pathogens, causing life-threatening hospital infections. This peptide's combination of extraordinary potency and wide safety margin makes it one of the most promising AMP candidates against this threat.
Questions still open
- Does the Aib-modified peptide maintain potency in animal infection models?
- Can it be manufactured at scale for clinical use?
- Would resistance develop against this membrane-targeting mechanism?
Common questions
Why is this peptide different from antibiotics?
What makes this peptide safer than other antimicrobials?
Read the original research
Rational Design of Helix-Stabilized Antimicrobial Peptide Foldamers Containing α,α-Disubstituted Amino Acids or Side-Chain Stapling.
ChemPlusChem, 85(12), 2731-2736
Citation
Hirano, Motoharu; Saito, Chihiro; Goto, Chihiro; Yokoo, Hidetomo; Kawano, Ryuji; Misawa, Takashi; Demizu, Yosuke. (2020). Rational Design of Helix-Stabilized Antimicrobial Peptide Foldamers Containing α,α-Disubstituted Amino Acids or Side-Chain Stapling.. ChemPlusChem, 85(12), 2731-2736. https://doi.org/10.1002/cplu.202000749